# OnCo record avelumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/avelumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "avelumab" ;
  schema:name "Avelumab"@en ;
  schema:description "Avelumab is a PD-L1 blocker given as maintenance after chemotherapy for advanced bladder cancer, which lengthened survival by about seven months."@en ;
  schema:url <https://onco.cc/drugs/avelumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Avelumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21083261> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Avelumab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-L1)" ;
  schema:alternateName "Bavencio" ;
  onco:approval "US 2017: Merkel cell carcinoma; urothelial cancer after platinum (accelerated)", "US 2020: Maintenance after first-line platinum in advanced urothelial cancer" ;
  onco:acceleratedApproval "US 2017-03-23: Treatment of adults and pediatrics patients 12 years and older with metastatic merkel cell carcinoma (MCC)", "US 2017-05-09: Locally advanced or metastatic urothelial carcinoma following diease progression on platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2020-06-30: Locally advanced or metastatic urothelial carcinoma following diease progression on platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy", "US 2023-09-06: Treatment of adults and pediatrics patients 12 years and older with metastatic merkel cell carcinoma (MCC)" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/merkel-cell-carcinoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/javelin-bladder-100/>, <https://onco.cc/trials/nct03228667/>, <https://onco.cc/trials/nct03260023/>, <https://onco.cc/trials/nct03547973/>, <https://onco.cc/trials/nct03815643/>, <https://onco.cc/trials/nct05327530/>, <https://onco.cc/trials/a-brave/> .